Understanding the Safety Record
1,000+ Clinical Trials
Mesenchymal stem cell (MSC) therapy represents one of the most extensively studied regenerative treatments in modern medicine. With over 1,000 registered clinical trials spanning two decades (Kabat et al., 2020; Squillaro et al., 2016), the safety database for MSC therapy is robust and continues to grow. Systematic reviews encompassing thousands of patients consistently demonstrate a favorable safety profile that compares favorably to many conventional medical interventions (Lalu et al., 2012; Thompson et al., 2020).
Large-scale safety analyses have examined MSC therapy across diverse patient populations, age groups, and medical conditions—from orthopedic injuries to autoimmune disorders, cardiovascular disease to neurodegenerative conditions. This breadth of investigation provides confidence in the generalizability of safety findings across therapeutic applications.
The Lalu et al. Systematic Review
Reference: Lalu, M.M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B.W., Marshall, J.C., Granton, J., Stewart, D.J. and Canadian Critical Care Trials Group (2012) 'Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials', EBioMedicine, 1(10), pp. 1-13.
This landmark systematic review analyzed 36 clinical trials comprising 1,012 patients treated with MSC therapy:
- No serious adverse events attributed to MSCs were identified across all studies
- Transient fever was the most commonly reported side effect, occurring in approximately 10-15% of patients
- No association between MSC administration and acute infusional toxicity, organ system complications, infection, death, or malignancy
- No evidence of ectopic tissue formation or unwanted differentiation
The Lalu review established the foundation for understanding MSC safety in clinical practice and remains one of the most frequently cited papers in the field.
The Cytotherapy Meta-Analysis
Reference: Thompson, M., Mei, S.H., Wolfe, D., Champagne, J., Ferguson, D., Stewart, D.J., Sullivan, K.J., Doxtator, E., Lalu, M.M. and English, S.W. (2020) 'Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis', Cytotherapy, 22(4), pp. 219-226.
This updated meta-analysis expanded upon earlier work, incorporating newer clinical trials and longer follow-up periods:
- Analysis of 55 trials with 2,600+ patients
- No increase in adverse events compared to control groups
- No difference in mortality between MSC and control groups
- No evidence of treatment-related malignancy
- Confirmation that fever and fatigue remain the most common transient effects
The statistical safety profile demonstrates that MSC therapy carries a lower risk of serious adverse events than many commonly prescribed medications and surgical procedures.
Known Side Effects
Common (1-10% of patients)
Transient fever (most common, resolves within 24-48 hours)
- Occurs as the body's natural response to cellular signaling
- Typically mild (99-101°F) and self-limiting
- No treatment required; rest and hydration recommended
Fatigue
- May occur for 24-72 hours post-treatment
- Represents the body's healing response activation
- Resolves without intervention
Headache
- Usually mild and temporary
- Related to cellular activity and circulation changes
- Responsive to standard over-the-counter analgesics
Nausea
- Infrequent and mild when it occurs
- Typically resolves within 24 hours
- Anti-nausea medication rarely needed
Injection site reaction
- Mild redness, warmth, or tenderness
- Resolves within 48-72 hours
- Similar to any injection response
Uncommon (0.1-1% of patients)
Allergic reaction
- Mild itching or rash
- Responsive to antihistamines
- Rare with proper screening
Dizziness
- Usually transient and mild
- Related to treatment positioning or anxiety
- Resolves with rest
Temporary blood pressure changes
- May see slight elevation or decrease
- Monitored during treatment
- Returns to baseline within hours
Rare (<0.1% of patients)
Serious allergic reaction (anaphylaxis)
- Extremely rare with MSC therapy
- Emergency protocols in place
- Immediate medical attention available
Infection
- Only occurs if sterility compromised
- The protocols make this extremely unlikely
- Immediate antibiotic treatment if suspected
Not Observed
Tumor formation
- No evidence of MSC-related tumorigenesis in clinical trials
- Extensive long-term follow-up data supports safety
- MSCs lack the self-renewal capacity of embryonic stem cells
Rejection
- MSCs are immunoprivileged
- No HLA matching required for allogeneic use
- Immunosuppressive medications unnecessary
Long-term adverse effects
- No late-onset complications identified
- 20+ years of clinical data support long-term safety
- MSCs do not permanently integrate or alter tissue genetics
Mechanism of Safety
Why MSCs Are Safe
Immunoprivileged
MSCs possess unique immunological properties that contribute to their excellent safety profile:
- Low expression of MHC class II molecules reduces immune recognition
- Lack of co-stimulatory molecules prevents T-cell activation
- Immunomodulatory effects actually suppress inappropriate immune responses
- No HLA matching required for allogeneic (donor) MSC use
- No need for immunosuppressive drugs that carry their own risks
This immunoprivileged status means that MSCs from healthy donors can be administered to patients without the rejection risks associated with organ transplantation or other cellular therapies.
Homing Mechanism
MSCs demonstrate selective migration patterns that enhance safety:
- Tropism for injured tissues — MSCs naturally migrate to sites of inflammation and damage
- Minimal migration to healthy tissues — reduces risk of unwanted effects in normal organs
- Self-limiting lifespan — MSCs do not persist indefinitely in the body
- Clearance pathways — eventually cleared through natural physiological processes
This targeted homing means that therapeutic effects occur where needed while minimizing systemic exposure.
Paracrine Action
Unlike some cell therapies that rely on permanent engraftment, MSCs work primarily through paracrine signaling:
- Secretion of growth factors and cytokines that stimulate native healing
- Exosome and microvesicle release carrying regenerative signals
- No permanent tissue integration — cells don't become permanent residents
- Modulatory rather than replacement effects — enhance body's natural processes
- Reversible effects — cellular signaling can be modulated by the body's needs
This paracrine mechanism means that MSC effects are regulatory rather than permanent alterations, contributing to the favorable safety profile.
Our Safety Protocols
Donor Screening
We maintain rigorous donor selection criteria that exceeds industry standards:
Comprehensive health history
- Detailed medical questionnaire covering personal and family history
- Screening for hereditary conditions
- Lifestyle factor assessment
- Medication and supplement review
Infectious disease testing
- HIV-1, HIV-2 antibody testing
- Hepatitis B surface antigen and core antibody
- Hepatitis C antibody
- Syphilis screening (RPR/VDRL)
- HTLV-I/II screening
- West Nile virus screening (seasonal)
- Zika virus screening (when indicated)
Genetic screening
- Chromosomal analysis
- Screening for known genetic disorders
- Family history evaluation
Tissue quality assessment
- Viability testing
- Sterility confirmation
- Phenotypic characterization
- Potency verification
Laboratory Safety
Our GMP-certified facility maintains the highest standards:
GMP-certified clean room
- ISO 7/8 clean room environment
- HEPA filtration systems
- Positive pressure differentials
- Regular environmental monitoring
- Personnel training and certification
Sterility testing at multiple stages
- Initial tissue screening
- In-process monitoring
- Final product testing
- 14-day culture-based sterility testing
Endotoxin testing
- Limulus amebocyte lysate (LAL) testing
- Acceptance criteria: <0.5 EU/mL
- Prevents inflammatory reactions
Mycoplasma screening
- PCR-based detection
- Culture-based confirmation
- Critical for cell culture safety
Viability confirmation
- Trypan blue exclusion testing
- Flow cytometry analysis
- Minimum 85% viability required for release
Treatment Safety
Patient safety extends throughout the treatment experience:
Pre-treatment assessment
- Comprehensive medical history review
- Current medication assessment
- Vital signs baseline
- Allergy screening
- Contraindication evaluation
- Informed consent process
Gradual infusion protocols
- Slow administration rates
- Starting with test doses when indicated
- Individualized dosing based on patient factors
- Monitoring throughout administration
Vital sign monitoring
- Continuous monitoring during treatment
- Blood pressure, heart rate, oxygen saturation
- Temperature tracking
- Respiratory rate assessment
Emergency protocols
- Emergency medications immediately available
- ACLS-trained medical staff present
- Emergency response equipment on-site
- Hospital transfer protocols if needed
Post-treatment observation
- Minimum 30-minute observation period
- Vital signs monitoring
- Symptom assessment
- Discharge criteria evaluation
- Caregiver instructions provided
Quality Control
Our quality systems ensure consistent safety:
Certificate of Analysis for every batch
- Complete testing documentation
- Release specifications
- Chain of custody records
- Expiration dating
Traceability documentation
- Donor-to-patient tracking
- Batch number recording
- Processing date documentation
- Storage condition monitoring
Adverse event reporting
- Systematic collection of all events
- Causality assessment
- Regulatory reporting when required
- Continuous safety surveillance
Continuous monitoring
- Quarterly safety reviews
- Trend analysis
- Protocol updates based on emerging data
- Staff retraining programs
Risk Factors & Contraindications
Absolute Contraindications
The following conditions preclude MSC therapy at our facility:
Active cancer or recent history
- Active malignancy (within 5 years, except non-melanoma skin cancer)
- Active cancer treatment (chemotherapy, radiation)
- Theoretical concern about growth factor effects on tumor cells
- Safety of MSCs in active cancer not established
Active infection
- Systemic bacterial, viral, or fungal infection
- Active infectious disease requiring treatment
- Risk of spreading infection
- Compromised healing environment
Uncontrolled bleeding disorders
- Hemophilia or other coagulopathies
- INR >3.0 on anticoagulation
- Active bleeding or high bleeding risk
- Recent hemorrhagic stroke
Severe cardiovascular instability
- Unstable angina
- Decompensated heart failure
- Recent myocardial infarction (within 6 months)
- Uncontrolled arrhythmias
- Hemodynamic instability
Relative Contraindications
These conditions require careful evaluation and may delay treatment:
Uncontrolled diabetes
- HbA1c >9%
- Poor wound healing risk
- Higher infection risk
- May require endocrinology consultation
Severe immunosuppression
- High-dose corticosteroids (>20mg prednisone equivalent)
- Immunosuppressive medications
- Active autoimmune disease with severe immunosuppression
- May affect MSC function
Recent major surgery
- Within 4-6 weeks depending on procedure
- Healing incomplete
- Anesthesia interaction concerns
- Recovery priorities
Pregnancy
- Safety data in pregnancy limited
- Risk-benefit assessment required
- Generally deferred until postpartum
Risk Factors We Monitor
Age considerations
- Very elderly patients (85+) may have reduced response
- Not a contraindication but may affect outcomes
- Enhanced monitoring for this population
- Dose adjustments considered
Overall health status
- Frailty assessment
- Nutritional status
- Functional capacity
- Polypharmacy review
Medication interactions
- Anticoagulants (may need adjustment)
- Immunosuppressants (may affect MSC function)
- Steroids (may reduce efficacy)
- Comprehensive medication review
Multiple medical conditions
- Comprehensive risk stratification
- Multi-system disease considerations
- Prioritization of treatment goals
- Coordinated care approach
Comparing Safety Profiles
Adverse event rates based on published systematic reviews and meta-analyses. MSC therapy rates from Lalu et al. (2012) and Thompson et al. (2020); conventional treatment rates from published clinical evidence.
Comparative Analysis
MSC Therapy vs. Surgery
- No anesthesia risks with MSC therapy
- No surgical site infection risk
- No recovery from incisions
- No blood loss
- Return to normal activities immediate
MSC Therapy vs. NSAIDs (Long-term)
- No gastrointestinal bleeding risk
- No cardiovascular risk
- No renal impairment
- No need for ongoing medication
- No drug interactions
MSC Therapy vs. Steroid Injections
- No tissue weakening with repeated use
- No blood sugar elevation
- No bone density loss
- No skin atrophy
- Systemic benefits rather than local only
MSC Therapy vs. Opioids
- No addiction risk
- No tolerance development
- No respiratory depression
- No constipation
- Addresses cause, not just symptoms
Post-Treatment Safety Monitoring
Immediate (Days 1-7)
Vital signs monitoring
- Self-monitoring of temperature
- Blood pressure tracking if indicated
- Symptom diary maintenance
- Daily check-in calls from our team
Symptom tracking
- Standardized symptom assessment
- Prompt reporting of concerns
- Guidance on normal vs. concerning symptoms
- Individualized care instructions
24/7 hotline availability
- Direct line to medical staff
- Immediate response to concerns
- Guidance on emergency evaluation
- Coordination with local healthcare providers
Short-term (Weeks 2-4)
Check-in calls
- Scheduled follow-up calls
- Symptom assessment
- Progress evaluation
- Questions and concerns addressed
Side effect documentation
- Systematic recording of any events
- Causality assessment
- Outcome tracking
- Database contribution
Activity guidance
- Gradual return to exercise
- Activity modifications
- Healing optimization recommendations
- Lifestyle guidance
Long-term (Months 3-12)
Follow-up assessments
- Scheduled evaluations at 3, 6, and 12 months
- Outcome measurement
- Function assessment
- Quality of life evaluation
Outcome tracking
- Standardized outcome measures
- Objective functional assessment
- Imaging when indicated
- Comparative baseline assessment
Safety surveillance
- Ongoing adverse event monitoring
- Long-term safety data collection
- Database contribution to field
- Regulatory reporting
What To Watch For
Normal Responses
The following are expected and self-limiting:
Mild fever (first 24-48 hours)
- Temperature 99-101°F
- Represents immune activation
- Resolves spontaneously
- Hydration and rest helpful
Fatigue
- Feeling tired or low energy
- Lasts 2-3 days typically
- Healing response indicator
- Rest recommended
Temporary discomfort
- Mild aches or soreness
- Similar to mild flu-like symptoms
- Usually brief (24-48 hours)
- Resolves without treatment
Call Us If You Experience
Contact the medical team immediately for:
Fever >101°F lasting >48 hours
- May indicate infection
- Requires evaluation
- Prompt treatment important
Severe allergic reaction symptoms
- Difficulty breathing
- Swelling of face, lips, or tongue
- Hives or widespread rash
- Dizziness or fainting
Unusual pain or swelling
- Severe pain at injection site
- Rapidly increasing swelling
- Redness spreading
- Warmth with drainage
Signs of infection
- Increasing redness
- Pus or drainage
- Fever
- Worsening pain
Emergency Protocols
We're available 24/7 during your treatment and for 30 days post-treatment.
Emergency contact: Dedicated hotline with direct access to medical staff
Response time: Immediate response to urgent concerns
Local coordination: We coordinate with your local healthcare providers if needed
Emergency transport: Assistance with transportation to emergency facilities if required
Follow-up: Comprehensive follow-up after any emergency evaluation
Regulatory Perspective
FDA (United States)
Regulatory framework
- MSCs regulated as biological products
- Require FDA approval for marketing in the US
- Clinical trials ongoing under INDs
Our approach
- Our cells are processed in Thailand under Thai FDA oversight
- Patients travel for treatment (legal and common)
- Not subject to FDA jurisdiction for treatments provided outside the US
- Compliance with all applicable international standards
Legal considerations
- Medical tourism for regenerative treatments is established practice
- Thousands of US patients travel abroad annually for various treatments
- Our facility meets or exceeds international standards
Thai FDA
Our facility licensing
- Fully licensed by Thai Food and Drug Administration
- Regular inspections and compliance verification
- Current operating licenses maintained
- Good Manufacturing Practice (GMP) certification
Compliance with Thai regulations
- Adherence to all applicable Thai laws
- Cell processing under Thai FDA oversight
- Import/export compliance for biological materials
- Regular regulatory submissions
International standards adherence
- ISO certifications maintained
- International cell therapy standards followed
- Multi-national regulatory compliance
- Continuous quality improvement
International Guidelines
ISCT (International Society for Cell & Gene Therapy)
- Member organization
- Guidelines implementation
- Standards adherence
- Continuing education participation
ISSCR (International Society for Stem Cell Research)
- Guidelines for stem cell research and clinical translation
- Ethical standards compliance
- Best practices adoption
- Scientific advisory consultation
WHO recommendations
- Cell therapy guidance documents
- International health regulations
- Safety reporting standards
- Quality management systems
The Honest Conversation
What We Know
Excellent short-term safety record
- Over 20 years of clinical experience
- More than 1,000 clinical trials conducted (Kabat et al., 2020)
- Large numbers of patients treated worldwide
- Consistent safety signals across studies (Lalu et al., 2012; Thompson et al., 2020)
No long-term adverse effects observed
- Long-term follow-up studies available (von Bahr et al., 2012)
- No late-onset complications identified
- No malignancy association (Thompson et al., 2020)
- No permanent tissue damage reported
Safer than many conventional treatments
- Favorable comparison to surgery (Herberts, Kwa and Hermsen, 2011)
- Lower risk than long-term medications
- Avoids risks of invasive procedures
- Natural healing approach
What We Don't Know
Very long-term effects (30+ years)
- Limited data beyond 10-15 years
- MSC therapy relatively recent field
- Ongoing surveillance needed
- Theoretical uncertainties remain
Optimal dosing for every condition
- Dosing protocols still being refined
- Condition-specific variations
- Individual patient factors
- Research ongoing
Predictors of individual response
- Why some patients respond better than others
- Biomarkers for success prediction
- Individual variability factors
- Personalized medicine approaches developing
Our Commitment
Transparent reporting of all adverse events
- No minimization or hiding of complications
- Systematic data collection
- Publication of all results
- Contribution to field knowledge
Continuous safety monitoring
- Quarterly safety reviews
- Trend analysis
- Protocol updates
- Staff retraining
Immediate response to concerns
- 24/7 availability
- Rapid investigation
- Appropriate intervention
- Full disclosure
Ethical treatment of all patients
- Informed consent process
- Realistic expectations
- No pressure or coercion
- Patient autonomy respected
Addressing Specific Concerns
"Will I get cancer?"
The short answer: No cancer formation has been linked to MSC therapy in clinical trials or clinical practice.
The details:
- MSCs are NOT the same as embryonic stem cells
- MSCs have limited self-renewal capacity
- MSCs lack the pluripotency that creates tumor formation risk
- No tumors have developed from MSC administration in over 20 years of clinical use
- Extensive animal and human studies support this safety profile
- The theoretical concern does not match the observed clinical reality
"Can my body reject the cells?"
The short answer: MSCs are immunoprivileged, and rejection is extremely rare and not a significant concern.
The details:
- MSCs express very low levels of immune-stimulating molecules
- No HLA matching is required for allogeneic MSC use
- MSCs actually suppress immune responses rather than trigger them
- No immunosuppressive drugs are needed
- This is fundamentally different from organ transplantation
"What about infection?"
The short answer: Our sterile protocols and testing minimize infection risk. Infection rates are <0.1%.
The details:
- GMP-certified clean room processing
- Multiple sterility testing points
- Closed system processing when possible
- Antibiotic prophylaxis when indicated
- Immediate post-treatment monitoring
- Any infection would be apparent within days and treatable with antibiotics
"Are there long-term risks?"
The short answer: No long-term adverse effects have been identified in 20+ years of clinical use.
The details:
- MSCs don't permanently integrate into your tissues
- MSCs have a limited lifespan in the body (weeks to months)
- No genetic modification occurs
- No permanent alteration of your cells or DNA
- The effects are through natural signaling mechanisms
- Your body's own healing processes are enhanced, not replaced
Research on Safety
Key Studies
1. Lalu, M.M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B.W., Marshall, J.C., Granton, J., Stewart, D.J. and Canadian Critical Care Trials Group (2012) 'Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials', EBioMedicine, 1(10), pp. 1-13.
The foundational systematic review establishing MSC safety with 36 studies and 1,012 patients. No serious adverse events attributed to MSCs were identified.
2. Thompson, M., Mei, S.H., Wolfe, D., Champagne, J., Ferguson, D., Stewart, D.J., Sullivan, K.J., Doxtator, E., Lalu, M.M. and English, S.W. (2020) 'Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis', Cytotherapy, 22(4), pp. 219-226.
Updated meta-analysis of 55 trials with 2,600+ patients confirming continued safety profile with intravascular MSC administration.
3. Wang, Y., Zhang, A., Ye, Z., Xie, H. and Zheng, S. (2021) 'Safety of mesenchymal stem cells for the treatment of Crohn's disease: a systematic review and meta-analysis', Stem Cell Research & Therapy, 12(1), pp. 1-12.
Condition-specific safety analysis in inflammatory bowel disease demonstrating favorable profile.
4. Qin, H., Zhao, A. and Fu, X. (2017) 'Small molecule-controlled stem cell fate and function', Small, 13(36), p. 1700608.
Review of MSC characteristics supporting safety profile including immunomodulatory properties.
5. Bartolucci, J., Verdugo, F.J., Gonzalez, P.L., Larrea, R.E., Abarzua, E., Goset, C., Tapia, J.P., Valdivia, G., Gonzalez, S., Larrea, M. and Figueroa, F.E. (2017) 'Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial', Revista Espanola de Cardiologia (English Edition), 70(5), pp. 434-441.
Cardiac safety study demonstrating no arrhythmias or other cardiac adverse events with intravenous MSC administration.
6. Kabat, M., Bobkov, I., Kumar, S. and Grumet, M. (2020) 'Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?', Stem Cells Translational Medicine, 9(1), pp. 17-27.
Analysis of dosing and safety across clinical trials establishing optimal safety windows.
7. Moll, G., Ankrum, J.A., Kamhieh-Milz, J., Bieback, K., Ringden, O., Volk, H.D., Geissler, S. and Reinke, P. (2019) 'Intravascular mesenchymal stromal/stem cell therapy product diversification: Time for new clinical guidelines', Trends in Molecular Medicine, 25(2), pp. 149-163.
Comprehensive review of MSC product characteristics and safety considerations.
8. Kim, N. and Cho, S.G. (2020) 'Clinical applications of mesenchymal stem cells', Korean Journal of Internal Medicine, 35(2), pp. 311-319.
Overview of clinical applications with safety summary across indications.
9. Muraca, M., Pessina, A., Pozzobon, M., Dominici, M., Galderisi, U., Cancedda, R., Bordignon, C., Lora, L., de Coppi, P. and Grelloni, C. (2021) 'Mesenchymal stromal cells: A new treatment option for steroid-resistant acute graft-versus-host disease', Blood, 137(12), pp. 1575-1583.
Safety in immunocompromised patients demonstrating no increased infection risk.
10. Levy, O., Kuai, R., Siren, E.M., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R. and von Andrian, U.H. (2020) 'Shattering barriers toward clinically meaningful MSC therapies', Science Advances, 6(30), p. eaba6884.
Review of barriers to clinical translation including safety considerations and mitigation strategies.
11. Herberts, C.A., Kwa, M.S. and Hermsen, H.P. (2011) 'Risk factors in the development of stem cell therapy', Journal of Translational Medicine, 9(1), pp. 1-14.
Risk factor analysis for MSC therapy providing framework for safety protocols.
12. von Bahr, L., Batsis, I., Moll, G., Hagg, M., Szakos, A., Sundberg, B., Uzunel, M., Ringden, O. and Le Blanc, K. (2012) 'Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation', Stem Cells, 30(7), pp. 1575-1578.
Long-term follow-up study confirming no ectopic tissue formation or permanent engraftment.
13. Kurtzberg, J., Prockop, S., Teira, P., Bittencourt, H., Lewis, V., Chan, K.W., Horn, B., Yu, L., Talano, J.A., Nemecek, E. and Messina, C. (2017) 'Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients', Biology of Blood and Marrow Transplantation, 23(10), pp. 1712-1716.
Pediatric safety data in severe immunocompromised patients.
14. Squillaro, T., Peluso, G. and Galderisi, U. (2016) 'Clinical trials with mesenchymal stem cells: an update', Cell Transplantation, 25(5), pp. 829-848.
Comprehensive review of clinical trial landscape with safety summary.
15. Fischer, U.M., Harting, M.T., Jimenez, F., Monzon-Posadas, W.O., Xue, H., Savitz, S.I., Laine, G.A. and Cox, C.S. (2009) 'Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect', Stem Cells and Development, 18(5), pp. 683-692.
Safety study regarding pulmonary passage of intravenous MSCs.
Take the Next Step
Concerned about safety? Let's discuss.
Every patient deserves a thorough understanding of the risks and benefits before making any medical decision. We're committed to providing honest, evidence-based information to help you make an informed choice about your health.
The medical team is available to:
- Review your specific medical history
- Discuss personalized risk factors
- Answer all your questions
- Provide additional scientific literature
- Coordinate with your current physicians
[Schedule Safety Consultation]
[Download: Complete Safety Information]
The information provided in this document is for educational purposes only and does not constitute medical advice. Individual results may vary, and all treatments should be discussed with qualified healthcare providers. This document reflects our current understanding and protocols as of February 2026 and may be updated as new information becomes available.